




Beyond Classic Chikungunya Fever



Severe and Atypical Manifestations in Children

Orasri Wittawatmongkol, MD.
Department of Pediatrics,
Siriraj Hospital Mahidol University


12-month Chikungunya virus disease case notification rate per 100 000 population, November 2024-October 2025

Map

17 Nov 2025



Countries with elevated risk for U.S. travelers



0.01-0.99/100,000 populations

- Brazil
- Colombia
- India
- Mexico
- Nigeria
- Pakistan
- Philippines
- Thailand

สถานการณ์ โรคไข้ป่าด้วยยุงลาย

ข้อมูลวันที่ 1 ม.ค. - 22 ต.ค. 2568

สัปดาห์ที่ 43

ผู้ป่วย

สะสม **1,332** ราย
รายใหม่ **+ 70** ราย

อัตราป่วย 2.01 / ประชากรและ cabin
พบผู้ป่วยสูงกว่าปี 2567 อยู่ 2.3 แห่ง¹
และพบแนวโน้มผู้ป่วยเพิ่มขึ้นทั่วประเทศเลย

เสียชีวิต

สะสม **0** ราย
รายใหม่ **0** ราย


อัตราป่วยตาย ร้อยละ 0.00

2 จังหวัด¹
ที่มีจำนวนป่วยสูง
• เลย
• เชียงใหม่

(ข้อมูลช่วง 4 สัปดาห์ล่าสุด)



Countries and Territories with Local Transmission of Chikungunya Virus




- CHIKV infections reported in > 100 countries
- The first outbreak in Asia in 1958, occurred in Bangkok, Thailand
- In Thailand 2019, a large outbreak of CHIKV resulted in > 13,000 cases in Bangkok and some provinces in the south, > 2,700 cases reported in Bangkok

Chikungunya Virus Infection

- Chikungunya (Makonde language) "that which bends up"
- Chikungunya virus (CHIKV): *Alphavirus* of the *Togaviridae* family
- First identified in 1952 in Tanzania

Transmission:

- Mosquito-borne, human to human by biting of infected female mosquito: *Aedes aegypti* and *Aedes albopictus*
- **Incubation period:** typically 3–7 days (range 1–12 days)
- **Mother to child transmission:** Intrapartum, when mother was viremic around the time of delivery
- **Rare in utero transmission, mostly during second trimester**
- **No reports of transmission virus through breastfeeding**




Clinical Manifestations

- Sudden-onset **fever**, severe **arthralgia**, headache, **skin rash**
- Rash: macular, maculopapular, bullous, skin blistering
- Conjunctival injection, photophobia
- Myalgia, disabling arthralgia and arthritis:
 - Migratory polyarthritis
 - Finger, wrist, ankle, elbow and knee joints:
most commonly affected
- Tenosynovitis, tendinitis or bursitis
- In adults, chronic arthralgia (>3 months) may last for several years
- Permanent joint destruction: rare



Atypical and severe, even fatal manifestations of CHIKV as well as evidence of vertical transmission were first described in 2005–2006 during an outbreak on Réunion Island



Chikungunya Case Definitions

by World Health Organization. Nicaragua, 20-21 May 2015

- **Typical case**: self-limited, non-severe exanthematous fever
- **Atypical case**: a laboratory-confirmed CHIKV patient presenting with neurological, cardiovascular, dermatological, ophthalmological, hepatic, renal, respiratory, or hematologic involvement
- **Severe case**: a laboratory-confirmed CHIKV-infected patient presenting with **at least one organ or system dysfunction that threatens life and requires hospitalization**

- อส: ไข้และซีมลง 1 วัน ก่อนมาโรงพยาบาล
- 1 วันก่อนมีไข้สูง ไม่มีไอหรือน้ำมูก ไม่มีคุลีน์ไส้อเจียน ไม่มีถ่ายเหลว ไม่มีปัสสาวะแสบขัด ไม่มีผื่นขึ้นตามตัว กินอาหารได้ตามปกติ
- 6 ชั่วโมงก่อน ซีมลง เรียกไม่รู้สึกตัว ตาลอย พูดเพ้อ ไม่มีเกร็งกระตุก ไม่มีปัสสาวะอุดจาระริด มีถ่ายเหลว 1 ครั้ง ไม่มีน้ำ เลือดปน

Acute encephalitis

Lumbar puncture:

Open pressure 24 cmH2O, Close pressure 16 cmH2O

CSF: clear, WBC 4, RBC 2, Protein 25 mg/dl, Sugar 76 mg/dl

EEG: Abnormal EEG: slow PDR for age

Interpretation: suggests mild encephalopathy

- PE: **T 42°C, BP 96/67 mmHg, HR 148 bpm, RR 28 /min, SpO2 97%, BW 42 kg (P97), Ht 136 cm (P50-75)**
- GA: A Thai girl, drowsiness, not pale, no jaundice, no cyanosis
- Skin: no rash, no petichiae
- CVS: normal S1 S2, no murmur
- RS: lungs - clear
- Abd: soft, no hepatosplenomegaly
- CNS: Drowsiness, not co-operate, E3V1M5, can localized pain, equally movement, Reflex 2+ all extremities, BBK: plantar flexion both, clonus: negative, stiff neck: negative, cranial nerves - intact

DATE	8/11/62	9/11/62	10/11/62	11/11/62	12/11/62	13/11/62	14/11/62
------	---------	---------	----------	----------	----------	----------	----------

Days after

Cefotaxime

Pain Scale

Acyclovir

CHEOPS

Oseltamivir

Weight

°F

°C

Kg

A4

105.8

41

A4

104.0

40

A3

102.2

39

A2

100.4

38

A1

98.6

37

A0

96.8

36

A0

95.0

35

Doxo

A4

105.8

41

A4

104.0

40

A3

102.2

39

A2

100.4

38

A1

98.6

37

A0

96.8

36

A0

95.0

35

148 136 124 70 100 109 104 96 109 114 98 94 96 96 96 98 96 124 98 86 112 80 110

26 32 30 24 24 24 20 28 22 20 27 20 20 26 20 29 20 20 20 20 22 22 90

98 72 94 98 94 20 22 20 20 20 20 20 20 20 20 20 20 20 20 20

SYSTOLIC

DIASTOLIC

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

99/64

CBC

Hb	13
HCT	37.8
MCV	80.4
WBC	14820
seg%	80.6
Lymph%	11.5
Mono%	7.8
Eos%	-
baso%	0.1
band%	-
Platelet	320000

CSF for meningoencephalitis multiplex PCR

<i>E.coli</i> K1	not detected
<i>H.influenzae</i>	not detected
<i>L.monozytogenes</i>	not detected
<i>N.meningitidis</i>	not detected
<i>S.agalactiae</i>	not detected
<i>S.pneumoniae</i>	not detected
CMV	not detected
Enterovirus	not detected
HSV1	not detected
HSV2	not detected
HSV6	not detected
human parechovirus	not detected
VZV	not detected
<i>C.neoformans/gatti</i>	not detected

Lab for specific pathogens

NP Wash	
Enterovirus Ag	negative
Enterovirus 71 Ag	negative
Influenza A Ag	negative
Influenza B Ag	Negative
Respiratory virus	Negative

Dengue	
NS1	negative
IgG	negative
IgM	negative

IFA for S.typhus	negative
IFA for M.typhus	negative
Blood for Chikungunya RNA	Positive
CSF Chikungunya RNA	Positive

Mycoplasma titer	Negative <1:40
------------------	----------------



Culture	
Hemoculture	Negative
Urine	Negative
CSF	Negative
Stool	Negative

RESEARCH ARTICLE

Re-emerging outbreaks of chikungunya virus infections of increased severity: A single-center, retrospective analysis of atypical manifestations in hospitalized children during the 2019 outbreak in Bangkok, Thailand

Artchavit Boonanek¹, Kulkanya Chokephaibulkit^{1,2}, Wanatpreeya Phongsamart¹, Keswadee Lapphra¹, Supattra Rungmaitree¹, Navin Horthongkham³, Orasri Wittawatmongkol^{1*}

The Bangkok Outbreak in 2019: Hospitalized Children with Confirmed CHIKV



ECSA-IOL strain with the E1:226A genotype (E1:K211E/E2:V264A),
which enhanced viral infectivity, dissemination, and transmission in *Aedes aegypti* mosquitoes

90% of Cases had Atypical Manifestations


- **Neurological** 22.6%, meningoencephalitis 16%
 - 15% in Brazil, 11% in Honduras, and 10% Reunion island
- Acute kidney injury 22.6%
- Nausea/vomiting 22.6%
- **Septic shock** 12.9%
- **Bullous skin lesions** 19.4%
- **Generalized erythroderma** 6.5%
- **Hyperpigmentation** 13% (centrofacial area and extremities)
“brownie nose” or the ‘Chik’ sign

PLEASE!



NO PHOTOS

Skin Manifestations of CHIKV infection



Pediatric CHIKV patients with neurological involvement

Patient No.	Sex	Age	Diagnosis	Days between fever and neurological onset	CSF Profile						Neuroimaging
					Protein (mg/dL)	Glucose (mg/dL)	CSF/ SGlu	RBC (cells/mm ³)	WBC (cells/mm ³)	RT-PCR	
1	M	8 y	Meningoencephalitis	2	17	70	0.84	0	2	NE	Normal CT brain
2	M	12 y	Encephalopathy	2	13	67	0.71	1	3	–	Not performed
3	M	8 y	Encephalopathy, septic shock, DIC, AKI, rhabdomyolysis	9	78	45	0.59	18,000	22	–	Not performed
4	F	8 y	Meningoencephalitis	2	44	51	0.56	65	2	+	Normal CT brain and MRI
5	M	7 m	Meningoencephalitis	2	30	71	0.67	67	1	NE	Normal CT brain
6	M	6 d	Congenital CHIKV, TTN, septic shock, hypotonia, OMD, meningoencephalitis	1	80	44	0.49	17,750	14	+	Lenticulostriate vasculopathy from U/S brain
7	M	4 d	Congenital CHIKV, DENV infection, sepsis, OMD, ASD, meningoencephalitis	1	50	61	0.45	1,260	5	+	Cystic changes in bilateral germinal matrix hemorrhage from U/S brain

All 6/7 of children developed neurological symptoms within 2 days of fever onset

Children with Severe CHIKV Presentations

Table 3. Clinical complications and underlying medical conditions of four children with severe CHIKV presentations.

Case	Sex	Age	Underlying medical condition(s)	Clinical complications
1	M	8 y	Asthma, ASD, left renal agenesis, MPHD	Shock, encephalopathy, rhabdomyolysis, upper GI bleeding, transaminitis, adrenal insufficiency, AKI
2	M	5 y	Asthma, global developmental delay	Shock
3	F	12 y	N/A	Shock, transaminitis, AKI
4	M	6 d	LGA, full-term	Congenital CHIKV, respiratory distress, shock, meningoencephalitis

Two Cases of Congenital CHIKV Infection at Siriraj Hospital 2019

- Mothers had typical non-severe CHIK infection 2 days before delivery
- Term babies developed fever Day 4th and Day 6th of life, maculopapular rash, sepsis-like symptoms, meningoencephalitis
- Both of them developed oromotor dysfunction and turned to be normal at within 2 months of age.
- One was hyperactive but had normal clinical development at 1 year 7 months of age
- The other was diagnosed with delayed speech at 2 years of age



Congenital CHIKV Infection

- First report during the Réunion Island outbreak 2005
- Perinatal transmission: 27.7–48.3% in Latin America
- Mother had CHIKV viremia during the perinatal period
- Onset of symptoms: median day 4 (range: 3–7) of life

Common features:

- Fever, rash, poor feeding, pain, edema or distal joint edema
- Petechiae, thrombocytopenia and lymphopenia
- Meningoencephalitis/encephalitis, encephalopathy, intracerebral hemorrhages, status epilepticus, multiorgan failure

A systematic review: 42 studies 266 babies with confirmed vertical CHIKV infection

- 70 % had fever
- 94 % sepsis-like syndrome requiring ICU admission,
- **Neurological manifestations (68.7 %):** hypoactivity, irritability, meningoencephalitis, seizures, and intracranial hemorrhage
- Dermatological lesions (55.2 %): maculopapular rash, hyperpigmentation, or bullous dermatosis;
- **Cardiovascular manifestations, 51.5 %**
- Hyperalgesia or diffuse limb edema, 46.2 %
- Respiratory symptoms 41.7 %
- **39.8 % developed motor, cognitive, or visual sequelae.**

Clinical Manifestations of Chikungunya in Children and Adults

Features	Children	Adults
Fever	Sudden onset, high-grade ($> 38.9^{\circ}\text{C}$), duration 1–8 d	
Skin	<ul style="list-style-type: none">• Maculopapular rash (33–60%)• Pigmentary changes (42%)• Bullous rash/skin blistering in 38–48% of infants < 6 mo of age	<ul style="list-style-type: none">• Maculopapular rash on trunk and limbs (35–50%)• Pigmentary changes (rare)• Bullous rash/skin blistering or photosensitivity (rare)
Mucocutaneous	<ul style="list-style-type: none">• Oral ulcers (rare)	Oral ulcers (16%)
Musculoskeletal	<ul style="list-style-type: none">• Myalgia, arthralgia (30–50%)	<ul style="list-style-type: none">• Arthritis/arthralgia, symmetric, more commonly affecting distal joints (87–99%)• Tenosynovitis (common)• Back pain (more common)• Myalgia (60–93%)

Clinical Manifestations of Chikungunya in Children and Adults

Features	Children	Adults
Chronic joint manifestations	<ul style="list-style-type: none"> • Arthralgia/arthritis persistent for 2 years (5–11%) 	<ul style="list-style-type: none"> • Arthralgia persistent or recurrent for 1 y in up to 57% • Arthralgia/arthritis, persistent for 3–5 y (12%)
Hemorrhagic manifestations	<ul style="list-style-type: none"> • Purpura, ecchymoses (10%) • Severe bleeding from nose, gums, gut, and shock (up to 19% in neonates) 	<ul style="list-style-type: none"> • Purpura, ecchymoses (occasional) • Severe bleeding from nose, gums, gut, and shock (rare)
Neurological manifestations	<ul style="list-style-type: none"> • Headache (15%) • Seizures, acute encephalopathy, meningoencephalitis (14–32%) 	<ul style="list-style-type: none"> • Headache (40–81%) • Encephalopathy, meningoencephalitis, acute flaccid paralysis, Guillain–Barre syndrome (<0.1%)
Asymptomatic disease	<ul style="list-style-type: none"> • 35–40% (rare in neonates and infants) 	16–27%

Neurocognitive Outcome of Children Exposed to Perinatal Mother-to-Child Chikungunya Virus Infection: The CHIMERE Cohort Study on Reunion Island

Patrick Gérardin^{1,2,3,9*}, Sylvain Sampériz^{1,9}, Duksha Ramful^{1,2,4,11}, Brahim Boumahni¹¹, Marc Bintner¹, Jean-Luc Alessandri¹, Magali Carbonnier¹, Isabelle Tiran-Rajaoefera¹, Gilles Beullier⁵, Irénée Boya⁶, Tahir Noormahomed⁷, Jocelyn Okoï^{8,9}, Olivier Rollot², Liliane Cotte¹, Marie-Christine Jaffar-Bandjee¹, Alain Michault¹, François Favier², Monique Kaminski³, Alain Fourmaintraux¹, Xavier Fritel^{3,10,11}

- Compared the neurocognitive function at age 2 years

unexposed-uninfected
N=65

Exposed -uninfected
N=70

p-CHIKV-infected
children N=33

- 51% of infected children had global developmental delay (GND) compared to 15% of uninfected children (P=0.001).
- 75.0% of the children with a history of CHIKV encephalopathy had a Gross Neurologic Deficits (50% moderate, 25% severe) compared with 38.1% of children presented with “mild prostration”

CHIKV should be suspected in endemic countries and tested for in **febrile children, esp. those with **rash and neurological involvement**.**

THANK YOU!

